EcoDrugPlus

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSORLG00000003023
Gene Symbol: PARP2
4 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSORLG00000000752
Gene Symbol: PARP3
4 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSORLG00000014269
Gene Symbol: PORCN
4 Cross references
193 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSORLG00000008798
Gene Symbol: KCNMA1
4 Cross references
239 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSORLG00000006622
Gene Symbol: KCNMA1
4 Cross references
235 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2a

Ensembl ID : ENSORLG00000011020
Gene Symbol: KCNK2A
3 Cross references
209 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSORLG00000012076
Gene Symbol: KCNK3A
4 Cross references
200 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSORLG00000013245
Gene Symbol: KCNK9
4 Cross references
218 Possible Orthologues:

Potassium Intermediate/small Conductance Calcium-Activated Channel, Subfamily N, Member 4

Ensembl ID : ENSORLG00000006347
Gene Symbol: KCNN4
3 Cross references
187 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSORLG00000013847
Gene Symbol: KCNJ2A
4 Cross references
207 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSORLG00000016688
Gene Symbol: KCNJ3
4 Cross references
224 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSORLG00000027135
Gene Symbol: KCNJ5
4 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).